CA
NZ
UK
AU
IND
US
● Second-quarter results showed a swing to net profit, a significant milestone for the office landlord.
● Prime Medicine is a Cambridge, Massachusetts-based gene-editing biotech built around Prime Editing, a precision DNA-rewriting technology.
● Rocket Pharmaceuticals is a commercial-stage gene-therapy company built around treatments for ultra-rare genetic diseases.
● The company rejected a $5.25Takeoverbid, choosing to remain independent.
● The company achieved a GenentechPartnershipmilestone, a positive development overshadowed by broader cash burn concerns.
● Second-quarter results showed order volumes rising even as profitability nearly evaporated.
● Holley has spent the past two weeks working off a sharp post-earnings drop, with shares having fallen nearly 9%.
● Intellicheck shares crashed 25% despite delivering its fifth straight quarter of positive results.
● N-able shares fell more than a third in a single session after management cut full-year guidance on August 10, 2026.
● NeoVolta has been one of the more volatile names onNasdaqthis year, with shares trading anywhere from $1.36 to $7.13.
Please wait processing your request...